Fin Trust Capital Advisors, LLC Mannkind Corp Transaction History

Fin Trust Capital Advisors, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$3.02 - $5.37 $721 - $1,283	239 Added 38.8%	855 $4,000
Q3 2022 Oct 20, 2022	BUY	$2.99 - $4.35 $1,841 - $2,679	616 New	616 $2,000
Q1 2022 May 03, 2022	SELL	$2.62 - $4.45 $61,177 - $103,907	-23,350 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$4.05 - $5.37 $8,505 - $11,277	2,100 Added 9.88%	23,350 $102,000
Q3 2021 Nov 16, 2021	BUY	$3.89 - $5.48 $69,631 - $98,092	17,900 Added 534.33%	21,250 $92,000
Q2 2021 Aug 16, 2021	BUY	$3.61 - $5.45 $4,873 - $7,357	1,350 Added 67.5%	3,350 $18,000
Q1 2021 May 17, 2021	BUY	$3.14 - $6.14 $6,280 - $12,280	2,000 New	2,000 $8,000

245

148M

1.62M

802K

Ticker MNKD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 257,338,000
Market Cap $1.75B
Description
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocri...

Get notified when there are updates to the investment portfolio of Fin Trust Capital Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Fin Trust Capital Advisors, LLC with notifications on news.